Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $190.15 and last traded at $190.15, with a volume of 717 shares changing hands. The stock had previously closed at $197.44.
Genmab A/S Stock Performance
The business has a 50 day simple moving average of $209.38 and a 200-day simple moving average of $233.81. The firm has a market capitalization of $12.76 billion, a price-to-earnings ratio of 18.57 and a beta of 1.04.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- Overbought Stocks Explained: Should You Trade Them?
- 3 Must-Have ETFs Set to Dominate This Quarter
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Roth IRA Calculator: Calculate Your Potential Returns
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
